NM_000329.3(RPE65):c.1399C>G is a missense variant causing substitution of proline by alanine at position 467. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.00001898, with 2 alleles / 18384 total alleles in the East Asian population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with the NM_000329.3(RPE65):c.998+1G>A or NM_000329.3(RPE65):c.130C>T (p.Arg44Ter) variants confirmed in trans (PMID: 31273949, PMID: 30996589), which were previously classified pathogenic by the ClinGen LCA / eoRD VCEP (2 total points, PM3_Strong). At least one proband harboring this variant exhibits a phenotype including grey-white fundus albipunctatus‐like changes (2 pts), genotyping by exome sequencing that did not provide an alternative explanation for visual impairment (2 pts), night blindness with onset before age 5 years (1 pt), extinguished rod ERG responses (0.5 pts), and severely reduced cone ERG responses (1 pt), which together are specific for RPE65-related recessive retinopathy (6.5 total points, PMID: 31273949, PP4). Two other probands also meet the PP4 criteria including extinguished ERG, night blindness with onset in early childhood as well as additional consistent features such as white dot deposits in the mid-peripheral retina, and reduced visual acuity (PP4; PMID: 31273949). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 1 similarly affected relative in 2 different families, with the variant present in the compound heterozygous state (PP1; PMID: 31273949). The computational predictor REVEL gives a score of 0.891, which is above the ClinGen LCA/eoRD VCEP threshold of >0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). The variant exhibited 0% enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA / eoRD PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, PMID: 31580392). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PS3_Supporting, PM2_Supporting, PM3_Strong, PP1, PP3_Moderate, and PP4. (VCEP specifications version 1.0.0; date of approval 09/21/2023).